Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

Developed by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.

#guthealth #IBD’ “This finding was interesting, not only because it corroborated our previous study,” said Allen Lee, M.D., M ...

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

ORLANDO -- Longer hospitalization for flares of inflammatory bowel disease (IBD) was linked to greater risk of subsequent ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.

Dr. Axelrod was also recently appointed as a co-director for the Inflammatory Bowel Disease Center at NYU Langone. Steven Brant, MD. Rutgers University (New Brunswick, N.J.) Dr. Brant, a leader in ...

A study from University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue to experience symptoms, even in the absence of inflammation.

“These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease. If the magnitude of effect persists in the phase 3 programme, we ...